NEW YORK (GenomeWeb News) – Brahms subsidiary Cezanne will incorporate technology from Lumiphore in its diagnostic tests under two new agreements, Richmond, Calif.-based Lumiphore said today.
Brahms and Cezanne will use the Lumi4-Tb technology in development of current and future diagnostic tests under a non-exclusive agreement. In addition, Cezanne acquired exclusive rights to use the technology in diagnostic tests for Down's Syndrome, including tests for Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism, the company said.
The Lumiphore technology uses fluorescent-metal lanthanide detection reagents that have long emission lifetimes and offer high stability, multiplexing, and high signal-to-noise ratio, the firms said. Brahms' Kryptor analysis systems use time-resolved amplified cryptate emission technology for measuring molecular interactions.
Using the Lumi4-Tb technology "will not only increase the sensitivity of Brahms diagnostic tests, but will also allow the development of multiplexed assays," Cezanne CEO Emmanuel Bois said in a statement.
Financial terms of the agreement were not released.